F m Investments LLC Increases Stock Holdings in LivaNova PLC $LIVN

F m Investments LLC increased its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 21.0% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 74,606 shares of the company’s stock after acquiring an additional 12,964 shares during the period. F m Investments LLC’s holdings in LivaNova were worth $3,359,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Primecap Management Co. CA lifted its position in shares of LivaNova by 0.7% during the second quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company’s stock worth $208,954,000 after purchasing an additional 32,942 shares in the last quarter. Vanguard Group Inc. lifted its holdings in LivaNova by 13.5% in the 1st quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company’s stock worth $104,755,000 after buying an additional 316,993 shares in the last quarter. AQR Capital Management LLC boosted its position in LivaNova by 111.7% in the 1st quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company’s stock valued at $60,809,000 after buying an additional 829,115 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of LivaNova by 1.3% during the second quarter. Geode Capital Management LLC now owns 1,429,740 shares of the company’s stock valued at $64,374,000 after acquiring an additional 18,551 shares in the last quarter. Finally, Artisan Partners Limited Partnership grew its stake in shares of LivaNova by 112.9% during the second quarter. Artisan Partners Limited Partnership now owns 1,247,609 shares of the company’s stock valued at $56,167,000 after acquiring an additional 661,480 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Price Performance

Shares of LIVN opened at $63.30 on Friday. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $64.08. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -16.27 and a beta of 1.00. The stock has a 50 day moving average of $54.15 and a 200-day moving average of $50.16.

Wall Street Analysts Forecast Growth

LIVN has been the topic of several recent analyst reports. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of LivaNova in a research report on Tuesday. The Goldman Sachs Group set a $55.00 price target on shares of LivaNova and gave the stock a “neutral” rating in a research report on Wednesday, October 1st. Robert W. Baird lifted their price target on shares of LivaNova from $63.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. Finally, Barclays upped their price target on shares of LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, August 21st. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, LivaNova currently has an average rating of “Moderate Buy” and an average price target of $62.43.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.